ClinicalTrials.gg
RecruitingNCT07122258Updated Mar 5, 2026

Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

An interventional study of CAROL NSCLC treatment Device in NSCLC (Non-small Cell Lung Cancer), sponsored by Tau Medical Australia Pty Ltd. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Tau Medical Australia Pty Ltd · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia — 122 open to participants now, 213 under way, 82 of them phase 3. Carcinoma, Non-Small-Cell Lung · Australia.

Planned enrollment
477th of 486
7 · median 271
Started
2026
with 30 others
No phase
7 of 499
2 open now
Primary completion
2027-03
later than 67 of 212 live
Registered
456th of 499
by date

Among the 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia, this one is the 477th largest by planned enrollment of the 486 interventional ones that give a count, is one of 31 that started in 2026, is one of 7 with no phase, reaches primary completion later than 67 of the 212 other live ones, and was the 456th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

122 of the 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia, or all of them as a file.
02

Study summary

This study aims to evaluate the safety of the CAROL device for treating lung tumors in patients diagnosed with non-small cell lung cancer (NSCLC) with tumor size ≤ 2 cm (cT1b). The primary objective is to assess safety by monitoring and grading adverse events using the CTCAE v5.0 criteria at one month following the procedure.

03

Conditions studied

  • NSCLC (Non-small Cell Lung Cancer)

Keywords

  • CAROL
  • TAU MEDICAL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Those who meet all the following criteria are eligible to participate in the clinical trial.

  1. Adults 18 years of age or older at the time of screening
  2. NSCLC tumour(s)≤ 2 cm (cT1b) suitable for resection
  3. Suitable candidate for resection per standard of practice (Lobectomy)
  4. NSCLC is confirmed pathologically for the tissue that will be ablated
  5. Location of tumour:

    • ① in outer one thirds of lung (between outermost 1/3 measured by tumour centre),
    • ② if the centre of the tumour is located within the outermost 1/3, inclusion will proceed,
    • ③ anticipation that resection (lobectomy) would remove all gross tumour and ablation with grossly negative margins,
    • ④ one or more radiofrequency ablation (RFA) applications would target entire margin according to the RFA plan
  6. Signed free and as prescribed by hospital policies.

Exclusion criteria

Exclusion Criteria:

Those who meet any of the following criteria are excluded from this clinical trial.

  1. Centralised tumour (inner most one third) not amenable to resection (abutting main stem bronchus, main pulmonary artery branches, oesophagus or trachea)
  2. Other primary lung tumours
  3. Tumour is associated with vulnerable zone of pleural effusion
  4. If the centre of the tumour is not located within the outermost 1/3, exclusion will proceed
  5. PFT: post-bronchodilator forced expired volume in on second () or forced vital capacity (FVC) ≤60% predicted, diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 50% predicted
  6. Patients with evidence of severe chronic pulmonary disease including asthma, (COPD), or Interstitial Lung Disease (ILD).
  7. Requirement of supplemental oxygen at rest or exercise
  8. Hospitalization for cardiac disease within the preceding 3 months
  9. Liver enzymes ( [ALT], Alkaline Phosphatase [ALP], Aspartate Aminotransferase [AST]) or total >1.5 (ULN)
  10. Serum creatinine > 2 mg/dl
  11. Recent infection (within 30 days)
  12. Receiving medication or prednisone > 20 mg/day (or equivalent)
  13. Pre-existing implants - either within the airways or any other location - that impede navigation to or visualisation of the target lesion, in the opinion of the investigator
  14. Pregnant or breastfeeding women and those of who are not practicing a reliable form of .
  15. Disorder of coagulation, history of severe haemoptysis, or receiving anticoagulant medication. Antiplatelet medication is permitted provided that the medication can be held a minimum of 7 days prior to the procedures and 10 days post-procedures, where this refers to both the ablation and surgical procedures
  16. Any condition or anatomical factor that, in the opinion of the investigator or reviewer, may interfere with the safety of the patient, the conduct of the procedure, or evaluation of the study objectives (e.g. severe bronchial narrowing, wall compromise)
  17. Any tumour characteristic that in the opinion of the investigator or reviewers may interfere with the safety of the patient or evaluation of the study objectives
  18. to complete neuromuscular blockade during the ablation procedure
  19. Implantable cardiac devices such as pacemakers or defibrillators, especially with unipolar electrode configurations
  20. Known or allergy to gallium, indium, or other components of the conformable electrode
  21. Medically inoperable conditions
  22. Participant who is currently participating in, or planning to participate in (during the course of the trial), another non-observational clinical research study
  23. Participants who have participated in a non-observational clinical research study within either the past 30 days or who are still within the intervention's (whichever is longer)
  24. Participant who, in the opinion of the investigator, is not suitable for participation in the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    CAROL Device Treatment for Early-Stage NSCLC

    Participants in this single-arm study will undergo treatment with the CAROL device for localized lung tumors (NSCLC ≤ 2 cm, cT1b). All participants will receive a single CAROL procedure using a conformable electrode, followed by surgical resection of the tumor. The first 3 sentinel participants will receive a maximum dose of 0.3 mL of the conformable electrode. The next 4 participants will receive up to 2.0 mL. Safety and preliminary efficacy will be assessed through scheduled follow-up visits, including imaging, pulmonary function testing, laboratory assessments and pain monitoring. Adverse events will be monitored throughout the study, with grading based on CTCAE v5.0, specifically focusing on "Respiratory, thoracic, and mediastinal disorders." The study includes visits at screening, pre-procedure, post-procedure (24-36 hours), pre- and post-resection, and follow-up at approximately one and three months.

    Device: CAROL NSCLC treatment Device

Interventions

  • DeviceCAROL NSCLC treatment Device

    Participants in this single-arm study will undergo treatment with the CAROL device for localized lung tumors (NSCLC ≤ 2 cm, cT1b). All participants will receive a single CAROL procedure using a conformable electrode, followed by surgical resection of the tumor. The first 3 sentinel participants will receive a maximum dose of 0.3 mL of the conformable electrode. The next 4 participants will receive up to 2.0 mL. Safety and preliminary efficacy will be assessed through scheduled follow-up visits, including imaging, pulmonary function testing, laboratory assessments and pain monitoring. Adverse events will be monitored throughout the study, with grading based on CTCAE v5.0, specifically focusing on "Respiratory, thoracic, and mediastinal disorders." The study includes visits at screening, pre-procedure, post-procedure (24-36 hours), pre- and post-resection, and follow-up at approximately one and three months.

06

What researchers measure

Primary outcomes

  1. Common Terminology Criteria for Adverse Events(CTCAE)

    Graded using CTCAE grade (v5.0) criteria(CTCAE) The CTCAE utilizes a scale ranging from Grade 1 (mild) to Grade 5 (death-related) to classify the severity of adverse events. A higher CTCAE grade indicates increased severity of the adverse event, signifying a worse outcome.

    Time frame: 1 month post-procedure

Secondary outcomes

  1. Device success

    Success rate of CAROL device positioning at the target site The success rate of CAROL device positioning at the target site immediately after application, as assessed by fluoroscopic imaging and /or bronchoscopic visualization during the procedure. Proper positioning is defined as complete coverage of the target segmental bronchus by the ablation electrode without malposition or dislodgement. Frequencies and percentages will be presented to summarise the success rate.

    Time frame: Immediately after application (measured by imaging during the procedure)

  2. Procedural success

    Successful delivery of the ablation treatment for lung cancer using the CAROL system, performed according to the Instruction for Use (IFU) and treatment plan. Success will be determined based on the following criteria: Successful delivery of the CAROL catheter to the target site Successful injection of the Conformable Electrode (E-GaIn) Achievement of target ablation temperature Retrieval of the device without malfunction

    Time frame: Immediately after procedure (intraoperative and early postoperative period)

  3. Procedural success

    Pathological analysis Pathological evidence of effective ablation will be evaluated using hematoxylin and eosin (H\&E) staining to assess tissue viability. The extent of the coagulative necrotic zone relative to the tumor location will be quantified by pathologists. Descriptive statistics (mean, range) will summarize the extent of ablation effectiveness.

    Time frame: 5 ~ 10 days after lung resection

  4. Procedural success

    Imaging data evaluation Imaging data from computed tomography (CT) scans will be assessed to evaluate the extent of ablation, including lesion size and ablation margin relative to baseline. Measurements will be reviewed by radiologists using standard radiologic assessment criteria. Descriptive statistics will be presented for changes in treated areas.

    Time frame: 2~9 days after the CAROL procedure

Other outcomes

  1. Evaluation of Quality of Life scores

    Evaluation of Quality of Life scores(EQ-5D) The EQ-5D questionnaire will be used to assess patient's health-related quality of life. The EQ-5D includes 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each scored on 5 levels. Scores will be converted to an index value ranging from -0.594 (worst health state) to 1.000 (perfect health), based on country-specific value sets. Higher scores indicate better health-related quality of life.

    Time frame: 2~9 days after CAROL the procedure

  2. Evaluation of pain scores

    Visual Analogue Scale (VAS) Pain intensity will be assessed using the Visual Analogue Scale (VAS), a validated instrument consisting of a 10 cm horizontal line anchored by "no pain" (0) and "worst imaginable pain" (10). Participants will be asked to indicate their current level of pain on the scale. Higher scores indicate greater pain severity.

    Time frame: 2~9 days after the CAROL procedure

  3. Predicted and actual volume of liquid metal delivered

    The volume of Conformable Electrode (E-GaIn) predicted during the planning phase will be compared with the actual volume delivered during the CAROL procedure. Measurements will be obtained from procedure records and delivery system readouts. Differences will be quantified in milliliters (mL) and summarized using descriptive statistics.

    Time frame: 6~14 days after the CAROL procedure

  4. Predicted and actual ablation size

    The ablation size predicted during pre-treatment planning will be compared to the actual ablation zone measured by post-procedural imaging. Ablation volume will be quantified in cubic centimeters (cm3) using CT or MRI data, and descriptive statistics will be used to summarize differences.

    Time frame: 6 to 14 days after the CAROL procedure

  5. Distribution pattern of conformable electrode in varying bronchial anatomies

    CT images will be used to assess the spatial distribution of the Conformable Electrode (E-GaIn) across different bronchial structures. Anatomical coverage (e.g., lobar/segmental bronchi), symmetry, and dispersion pattern will be visually classified and quantitatively measured by independent radiologists. Descriptive statistics will summarize the observed distribution patterns.

    Time frame: Day 23 to Day 37 after the CAROL procedure

  6. Feasibility of procedural planning in various bronchial geometries

    The feasibility of procedural planning will be assessed based on whether the planned delivery paths through bronchial geometries were technically achievable during procedure simulation using CT-based airway mapping.

    Time frame: Day 23 to Day 37 after the CAROL procedure

  7. Accuracy of procedural planning in various bronchial geometries

    Accuracy will be assessed by comparing the planned device path (based on CT-based bronchial mapping) with the actual path and final position as observed in post-procedure CT imaging. The deviation between the planned and actual paths will be measured in millimeters in three-dimensional space by independent radiologists. Descriptive statistics (mean, standard deviation, and range) will be used to summarize the accuracy for each bronchial geometry type (e.g., lobar, segmental).

    Time frame: Day 23 to Day 37 after the CAROL procedure

  8. User feedback score on device usability and operating handling characteristics

    User feedback will be collected using a standardized questionnaire assessing device usability and operating handling characteristics, including perceived ease of use, catheter maneuverability, and procedural confidence. Responses will be summarized using descriptive analysis of response frequencies and thematic grouping of any free-text comments.

    Time frame: Day 23 to Day 37 after the CAROL procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 361 interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 97. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2025
First posted
Aug 14, 2025
StartEst.
Mar 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07122258
Lead sponsor
Tau Medical Australia Pty Ltd
Collaborators
Tau-MEDICAL Co., Ltd.
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Mar 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Daniel Steinfort, MD, PhD
Contact
Daniel.Steinfort@mh.org.au
+62 407 331 446
Jaeyoung Seo
Contact
sjy@tau-medical.com
+82 10 4844 3203

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion